Baby Aspirin

In 19,114 healthy older adults without prior cardiovascular events, daily 100 mg aspirin did not reduce all-cause mortality, cardiovascular events, or disability-free survival compared to placebo over 4.7 years; it increased major bleeding risk.

In 15,480 adults with diabetes but no prior cardiovascular events, daily 100 mg aspirin reduced serious vascular events by 12% versus placebo but increased major bleeding by 29%, with net benefit uncertain in lower-risk subgroups.

In 12,546 healthy adults aged 55+ at moderate cardiovascular risk without prior events, daily 100 mg aspirin did not significantly reduce composite cardiovascular events compared to placebo but increased gastrointestinal bleeding.

In 15,480 adults with diabetes but no prior cardiovascular events, daily 100 mg aspirin reduced serious vascular events by 12% versus placebo but increased major bleeding by 29%, with net benefit uncertain in lower-risk subgroups.

In 19,114 healthy older adults without prior cardiovascular events, daily 100 mg aspirin did not reduce all-cause mortality, cardiovascular events, or disability-free survival compared to placebo over 4.7 years; it increased major bleeding risk.

In 15,480 adults with diabetes but no prior cardiovascular events, daily 100 mg aspirin reduced serious vascular events by 12% versus placebo but increased major bleeding by 29%, with net benefit uncertain in lower-risk subgroups.

In 12,546 healthy adults aged 55+ at moderate cardiovascular risk without prior events, daily 100 mg aspirin did not significantly reduce composite cardiovascular events compared to placebo but increased gastrointestinal bleeding.